Inotuzumab ozogamicin (InO) is an antibody-drug conjugate approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Several clinical trials are investigating InO in combination with low-intensity chemotherapy or other anti-ALL-targeted therapies in the salvage and frontline settings, notably in older adults who often cannot tolerate intensive chemotherapy and tend to have higher-risk disease. InO is also increasingly used to bridge patients to hematopoietic stem cell transplantation (HSCT), in sequence with chimeric antigen receptor T-cell therapy, to eliminate measurable residual disease and to prevent post-HSCT relapse. Veno-occlusive disease/sinusoidal obstruction syndrome is a potential complication of InO treatment, particularly when followed by HSCT. Herein, the authors review the historical development and current status of InO, strategies for mitigating the risk of InO-related veno-occlusive disease/sinusoidal obstruction syndrome, and future directions for InO research and clinical use.Inotuzumab ozogamicin is approved to treat relapsed/refractory B-cell acute lymphoblastic leukemia but is increasingly used in other treatment settings. The authors review the historical development and current status of inotuzumab ozogamicin in adult B-cell acute lymphoblastic leukemia.

Kantarjian, H.M., Boissel, N., Papayannidis, C., Luskin, M.R., Stelljes, M., Advani, A.S., et al. (2024). Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. CANCER, 130(21), 3631-3646 [10.1002/cncr.35505].

Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions

Papayannidis, Cristina;
2024

Abstract

Inotuzumab ozogamicin (InO) is an antibody-drug conjugate approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Several clinical trials are investigating InO in combination with low-intensity chemotherapy or other anti-ALL-targeted therapies in the salvage and frontline settings, notably in older adults who often cannot tolerate intensive chemotherapy and tend to have higher-risk disease. InO is also increasingly used to bridge patients to hematopoietic stem cell transplantation (HSCT), in sequence with chimeric antigen receptor T-cell therapy, to eliminate measurable residual disease and to prevent post-HSCT relapse. Veno-occlusive disease/sinusoidal obstruction syndrome is a potential complication of InO treatment, particularly when followed by HSCT. Herein, the authors review the historical development and current status of InO, strategies for mitigating the risk of InO-related veno-occlusive disease/sinusoidal obstruction syndrome, and future directions for InO research and clinical use.Inotuzumab ozogamicin is approved to treat relapsed/refractory B-cell acute lymphoblastic leukemia but is increasingly used in other treatment settings. The authors review the historical development and current status of inotuzumab ozogamicin in adult B-cell acute lymphoblastic leukemia.
2024
Kantarjian, H.M., Boissel, N., Papayannidis, C., Luskin, M.R., Stelljes, M., Advani, A.S., et al. (2024). Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. CANCER, 130(21), 3631-3646 [10.1002/cncr.35505].
Kantarjian, Hagop M.; Boissel, Nicolas; Papayannidis, Cristina; Luskin, Marlise R.; Stelljes, Matthias; Advani, Anjali S.; Jabbour, Elias J.; Ribera, ...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/995495
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact